Adlai Nortye

Adlai Nortye (NASDAQ: ANL) is a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, with global R&D centers established in New Jersey, US, and Hangzhou, China. The company has built a global and robust pipeline through collaborations and internal discovery with six drug candidates in pipeline, with a strategic emphasis on oncology. Adlai Nortye has assembled a global management team and a scientific advisory board with industry leaders and influential scientists to provide important strategic guidance to its R&D, business development, and operational organizations. In addition to building its own R&D capabilities, the Company continues to seek and secure partnerships with leading multi-national pharmaceutical companies such as Eisai and Novartis, to fully realize the potential of its pipeline programs. The Company strives to become a global leader in the next wave of oncology therapies employing a combination therapy strategy. Its ultimate goal is to transform deadly cancer into a chronic and eventually curable disease.

网站

http://www.adlainortye.com

Adlai Nortye的外部链接

所属行业

制药业

规模

51-200 人

总部

杭州，浙江省

类型

上市公司

创立

2016

领域

生物医药和制药